The global ovarian cancer drugs market is anticipated to grow at a considerable CAGR of 13.8% during the forecast period (2022-2028). The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. The FDA is an agency within the U.S. Department of Health and Human Services to protect the public health and is responsible to assure the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The growth of the market is supported by launches of the approved novel drugs and the large number of treatment opportunities in the first-line advanced setting. Active biotech companies in the market include AstraZeneca Plc's, BioVaxys Technology Corp., Citius Pharmaceuticals, Inc., Bristol Myers Squibb, Roche Holding AG.
Browse the full report description of “Global Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report by Drug Class (PARP Inhibitors, Angiogenesis Inhibitors, PD-L1 Inhibitors), and by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, and Others) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/ovarian-cancer-drugs-market-size
A number of FDA approvals in 2020 were the first new therapies or the first in class permitted for certain conditions, and as a result the pipeline is continuing to grow at a rapid pace. For instance, in 2020, FDA approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. Some other FDA approvals in 2020 include in may 2020, FDA expanded the indication of olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Drug Class
o By Therapy
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- AstraZeneca PLC, Clovis Oncology, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc. and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Ovarian Cancer Drugs Market Report Segment
By Drug Class
• PARP Inhibitors
• Angiogenesis Inhibitors
• PD-L1 Inhibitors)
By Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others
Global Ovarian Cancer Drugs Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/ovarian-cancer-drugs-market-size